Receptor-directed therapy of T-cell leukemias and lymphomas

John C. Morris, Thomas A. Waldmann, John Edward Janik

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.

Original languageEnglish (US)
Pages (from-to)235-248
Number of pages14
JournalJournal of Immunotoxicology
Issue number2
StatePublished - Apr 2008


  • Antibody
  • Leukemia
  • Lymphoma
  • Receptor
  • T-cell

ASJC Scopus subject areas

  • Immunology
  • Toxicology


Dive into the research topics of 'Receptor-directed therapy of T-cell leukemias and lymphomas'. Together they form a unique fingerprint.

Cite this